Preview

Эпидемиология и Вакцинопрофилактика

Расширенный поиск

Достижения и перспективы вакцинопрофилактики папилломовирусной инфекции и ассоциированных заболеваний

https://doi.org/10.31631/2073-3046-2020-20-2-110-118

Полный текст:

Аннотация

Актуальность. Прошедшее десятилетие ознаменовано стремительными достижениями в области профилактики инфекций, вызываемых вирусом папилломы человека (ВПЧ) и ассоциированных заболеваний.

Цель. В обзоре обобщен многолетний мировой опыт и рассмотрена доказательная база влияния национальных программ вакцинации против ВПЧ на распространенность ВПЧ-инфекции, заболеваемость генитальными кондиломами и предраковыми цервикальными поражениями в клинической практике. Представлены результаты модельных исследований эффективности различных стратегий вакцинации для создания коллективного иммунитета, гендерно-нейтральной вакцинации и потенциала для элиминации онкогенных типов ВПЧ.

Вывод. Ликвидация ВПЧ-ассоциированных раков и, прежде всего, рака шейки матки, теперь является реалистичной перспективой.

Об авторе

Г. Н. Минкина
ФГБОУ ВО Московский государственный медико-стоматологический университет им. А. И. Евдокимова Минздрава России
Россия

Минкина Галина Николаевна − доктор медицинских наук, профессор кафедры акушерства и гинекологии

127473 Россия, Москва, ул. Делегатская 20/1



Список литературы

1. WHO. Human papillomavirus (HPV) and cervical cancer, 24.01.2019. Доступно на: https://www.who.int/ru/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer

2. Bruni L. The frequency of HPV infection worldwide. HPVWorld. March 2018, Year 2 Nº 35. Доступно на: https://www.hpvworld.com.

3. de Martel C., Plummer M., Vignat J. et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15; 141(4): 664−670. doi: 10.1002/ijc.30716.

4. Serrano B, Brotons M, Bosch FX, et al.. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47: 14−26. doi: 10.1016/j.bpobgyn.2017.08.006.

5. de Sanjosé, S. Tsu V.D. Spectrum of HPV related diseases. HPVWorld. March 2018, Year 2 Nº 36. Доступно на: https://www.hpvworld.com.

6. Bruni L, Albero G, Serrano B et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Russian Federation. Summary Report 10 December 2018. Доступно на: https://hpvcentre.net/index.php.

7. Грецова О. П., Костин А. А., Самсонов Ю. В. и др. Заболеваемость и смертность от злокачественных новообразований, ассоциированных с вирусом папилломы человека. Исследования и практика в медицине 2017; 4(3): 33 −50. https://doi.org/10.17709/2409-2231-2017-4-3-4.

8. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Каприн А. Д., Старинский В. В., Петрова Г. В., ред. М.: МНИОИ им. П. А. Герцена − филиал ФГБУ «НМИРЦ» Минздрава России; 2018. 250 с.

9. WHO. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017 Oct 13;35(43):5753-5755. doi: 10.1016/j.vaccine.2017.05.069. Доступно на: http://www.who.int/wer.

10. Arbyn M., Xu L., Simoens C. et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018. May 9; 5:CD009069.

11. Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 3; 364(5): 401−11. doi: 10.1056/NEJMoa0909537.

12. WHO. Vaccine in National Immunization Programme Update January 2020. Доступно на: https://www.who.int/immunization/monitoring_surveillance/en.

13. Garland S.M., Kjaer S.K., Muñoz N. et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016 Aug 15; 63(4): 519−27. doi: 10.1093/cid/ciw354.

14. Maver P.J., Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. Vaccine. 2018 Aug 28; 36(36): 5416−5423. doi: 10.1016/j.vaccine.2017.07.113.

15. Patel C., Brotherton J.M., Pillsbury A. et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018 Oct; 23(41). doi: 10.2807/1560-7917.ES.2018.23.41.1700737.

16. Department of Health and Ageing. Immunise Australia program: human papillomavirus (HPV). February 14, 2013. Доступно на: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv.

17. The National Human Papillomavirus (HPV) Vaccination Program Register. Доступно на: http://www.hpvregister.org.au/research/coverage-data.

18. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014 Oct;14(10):958-66. doi: 10.1016/S1473-3099(14)70841-2. Epub 2014 Aug 5.

19. Machalek DA, Garland SM, Brotherton JML et al. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. J Infect Dis. 2018 Apr 23;217(10):1590-1600. doi: 10.1093/infdis/jiy075.

20. Chow EPF, Machalek DA, Tabrizi SN et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 2017 Jan; 17(1): 68−77. doi: 10.1016/S1473-3099(16)30116-5.

21. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis. 2015 May; 15(5): 565 −80. doi: 10.1016/S1473-3099(14)71073-4.

22. Drolet M, Laprise JF, Brotherton JML et al. The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation. J Infect Dis. 2017 Dec 5; 216(10): 1205−1209. doi: 10.1093/infdis/jix476.

23. Read TRH, Hocking JS, Chen MY et al.. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011; 87(7): 544−7. https://doi.org/10.1136/sextrans-2011-050234.

24. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013; 346(apr181):f2032. https://doi.org/10.1136/bmj.f2032.

25. Chow EPF, Read TRH, Wigan R et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015; 91(3): 214−9. https://doi.org/10.1136/sextrans-2014-051813.

26. Smith MA, Liu B, McIntyre P, et al. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 2015 Jan 1; 211(1): 91 −9. doi: 10.1093/infdis/jiu370.

27. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Доступно на: https://kirby.unsw.edu.au/sites/default/files/kirby/report/KI_Annual-Surveillance-Report-2018.pdf.

28. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348(mar04 2):g1458. https://doi.org/10.1136/bmj.g1458.

29. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013; 11(1): 227. https://doi.org/10.1186/1741-7015-11-227.

30. Ogilvie GS, Naus M, Money DM et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. Int J Cancer. 2015 Oct 15; 137(8): 1931−7. doi: 10.1002/ijc.29508.

31. Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study. Int J Cancer. 2016 Jun 15; 138(12): 2867−74. doi: 10.1002/ijc.30035.

32. Luostarinen T, Apter D, Dillner J, Eriksson T, Harjula K, Natunen K, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018 May 15; 142(10): 2186−2187. doi: 10.1002/ijc.31231.

33. Guo F, Cofie L E, Berenson AB. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. Am J Prev Med. 2018 Aug; 55(2): 197−204. doi: 10.1016/j.amepre.2018.03.013.

34. Vänskä S, Auranen K, Leino T, et al. Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS One. 2013 Aug 29; 8(8): e72088. doi: 10.1371/journal.pone.0072088. eCollection 2013.

35. Bruni, L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016 Jul; 4(7): e453−63. doi: 10.1016/S2214-109X(16)30099-7.

36. Drolet M, Bénard É, Pérez N, et al. M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Jun 26. pii: S0140-6736(19): 30298−3. doi: 10.1016/S0140-6736(19)30298-3.

37. Lehtinen M, Luostarinen T, Vänskä S, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomised (III). Int J Cancer. 2018 Nov 1; 143(9): 2299−2310. doi: 10.1002/ijc.31618.

38. Lehtinen M, Baussano I, Paavonen J, et al. Eradication of human papillomavirus and elimination of HPV-related diseases − scientific basis for global public health policies. Expert Rev Vaccines. 2019 Feb; 18(2): 153−160. doi: 10.1080/14760584.2019.1568876.

39. Brisson M, Bénard É, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and metaanalysis of predictions from transmission-dynamic models. Lancet Public Health. 2016 Nov; 1(1): e8−e17. doi: 10.1016/S2468-2667(16)30001-9.

40. Elfström KM, Lazzarato F, Franceschi S, et al. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016 Jan 15; 213(2): 199−205. doi: 10.1093/infdis/jiv368.

41. Smith M, Canfell K. Impact of the Australian National Cervical Screening Program in women of different ages. Med J Aust 2016; 205: 359–64.

42. Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Dec 4, 2017. Доступно на: http://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening.

43. Office of the Prime Minister of Australia. A new vaccine to strengthen the health of young Australians. Oct 8, 2017. Доступно на: http://parlinfo.aph.gov.au/parlInfo/search/display/display.w3p;query=Id%3A%22media%2Fpressrel%2F5562151%22.

44. Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019 Jan; 4(1): e19−e27. doi: 10.1016/S2468-2667(18)30183-X.


Для цитирования:


Минкина Г.Н. Достижения и перспективы вакцинопрофилактики папилломовирусной инфекции и ассоциированных заболеваний. Эпидемиология и Вакцинопрофилактика. 2020;19(2):110-118. https://doi.org/10.31631/2073-3046-2020-20-2-110-118

For citation:


Minkina G.N. Achievements and Prospects of Vaccination against Human Papillomavirus Infection and Associated Diseases. Epidemiology and Vaccinal Prevention. 2020;19(2):110-118. (In Russ.) https://doi.org/10.31631/2073-3046-2020-20-2-110-118

Просмотров: 145


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-3046 (Print)
ISSN 2619-0494 (Online)